Dr. Alison D. Savage

Hematology Oncology | Hematology | Oncology
500 Sw Ramsey Ave, 
Grants Pass, OR 
Accepting New Patients
Offers Telehealth
500 Sw Ramsey Ave, 
Grants Pass, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alison Savage is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Savage is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Testicular Yolk Sac Tumor, and Bone Marrow Aspiration. Dr. Savage is currently accepting new patients.

Her clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OR
Hospital Affiliations
Fairchild Medical Center
Asante Ashland Community Hospital
Providence Medford Medical Center
Asante Three Rivers Medical Center
Asante Rogue Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ASANTE THREE RIVERS MEDICAL CENTER LLC
500 Sw Ramsey Ave, Grants Pass, OR 97527
Other Locations
ASANTE
2825 E Barnett Rd, Medford, OR 97504

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Experienced in Prothrombin Deficiency
Dr. Sean T. Hehn
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Sean T. Hehn
Hematology Oncology | Hematology | Oncology

Asante Three Rivers Medical Center LLC

500 Sw Ramsey Ave, 
Grants Pass, OR 
 (0.1 miles away)
541-472-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sean Hehn is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Hehn is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Hehn is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Sara A. Matar
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Sara A. Matar
Hematology Oncology | Hematology | Oncology

Asante Three Rivers Medical Center LLC

500 Sw Ramsey Ave, 
Grants Pass, OR 
 (0.1 miles away)
541-472-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sara Matar is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Matar is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Essential Thrombocythemia, Breast Cancer, and Paget Disease of the Breast. Dr. Matar is currently accepting new patients.

Experienced in Prothrombin Deficiency
Dr. Ashish D. Dwary
Hematology Oncology | Hematology | Oncology
Experienced in Prothrombin Deficiency
Dr. Ashish D. Dwary
Hematology Oncology | Hematology | Oncology

Asante Three Rivers Medical Center LLC

500 Sw Ramsey Ave, 
Grants Pass, OR 
 (0.1 miles away)
541-472-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashish Dwary is a Hematologist Oncology specialist and a Hematologist in Grants Pass, Oregon. Dr. Dwary is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Appendix Cancer, and Colorectal Cancer. Dr. Dwary is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Savage's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 27 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile